Study: NCT00833833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.